INTRODUCTION
In
recent years, the morbidity of fatty liver is increasing. Chinese
and western medicines to cure fatty liver have come one after another.
Therefore, it is of primary importance to select medicines that
can both lower serum lipid levels and protect the liver from diseases.
From June of 1997 to December of 1999, we employed Xuezhikang capsule
to treat 41 fatty liver patients so as to observe its various curative
effects. The detail of the study is in the following.
PATIENTS
AND METHODS
Subjects
41
in- and out-patients suffering fatty liver at different degree of
the hospital were selected as, 27 men, 14 women, aging from 31 to
76 years old with the average 43.76. They met the diagnose criteria
of fatty liver in B-Mode Ultrasonogram check and divided into three
categories: slight, moderate and severe. [1] Among them, 21 cases
suffered slight fatty liver symptom, 17 moderate and 3 severe. There
were 39 patients (95%) associated with no appetite, abdominal distention
and liver dull pain, 24 cases (58%) of overweight, 8 cases (20%)
of long-term alcohol addiction and 9 cases (21%) of diabetes II.
Patients with hyperlipoidemia resulted from renal, endocrine or
medicines were excluded from the trial.
Methods
1. Oral administration of 0.6 g Xuezhikang (0.3 g per capsule) each
time, twice a day after meal. One period lasted for 8 weeks and
the trial was carried out for 3 periods.
2. Before, after the treatment, fast blood samples were taken in
every period to determine the concentrations of ALT, AST, TG, TC,
LDL-C and HDL-C. At the same time, employing Hewlett Packard?8500
and B-Mode Ultrasonic tip 3.5 MHz to examine liver conditions and
recorded clinical changes.
3. Statistical Processing
Data was expressed in the form of means ± standard deviation
( X ± s). And t-test was utilized for data comparison.
RESULTS
All
symptoms changed after the treatment. It was found that some improvement
occurred after 1 period and dramatic improvement happened after
patients got 3 treatment periods. See Table 1.
The
changes of biochemical indexes after the treatment were listed in
Table 2.
It could be seen that after the Xuezhikang treatment, the concentrations
of TC, TG, LDL-C reduced significantly and HDL-C level increased
dramatically (P < 0.01). ALT and AST also obtained a distinct
reduction (P < 0.001). And the statistical difference was significant.
Table
I: Clinical Changes after Xuezhikang Treatment (cases) |
Symptom
|
Before
treatment
|
After
treatment alleviation(n)
|
After
treatment disappear(n)
|
Total
Efficacy(%)
|
Upper
abdominal distention |
37
|
17
|
19
|
92
|
Right
upper abdominal
Pull Pain |
21
|
3
|
17
|
95
|
Feeble |
39
|
5
|
34
|
100
|
No
appetite
|
14
|
1
|
13
|
100
|
Table
II. Changes of Serum Lipid Concentration and its Relevant Indexes
after Xuezhikang Treatment
( X ± s) (Total cases: 41) |
Serum
Lipid and Its Indexes
|
Before
treatment
|
After
treatment
|
P
Value
|
TC
(mmol/L) |
6.86
± 1.11
|
4.93
± 1.31
|
<
0.01
|
TG
(mmol/L) |
2.97
±0.51
|
1.23
± 0.41
|
<
0.01
|
HDL-C
(mmol/L) |
0.95
± 0.11
|
1.33
± 0.14
|
<
0.01
|
LDL-C
(mmol/L) |
4.31
± 0.49
|
3.03
± 0.79
|
<
0.01
|
ALT
(IU/L) |
122.32
± 56.13
|
41.09
± 21.03
|
<
0.001
|
AST
(IU/L) |
82.15
± 21.37
|
34.31
± 12.01
|
<
0.001
|
B-Mode
ultrosonogram change was given in Table III. It could be seen that
there was significant changes of B-Mode ultrosonogram after the
treatment.
treatme
Table
III. B-Mode Ultrasonogram Changes after Xuezhikang Treatment
(Total Case: 41) |
Degree
|
Before
Treatment
|
After
Treatment
|
Slight
|
21
(51%)
|
14
(34%)
|
Moderate
|
17
(41%)
|
6
(14%)
|
Severe
|
3
(8%)
|
0
(0%)
|
Total
|
41
(100%)
|
20
(48%)
|
Side-effects
Three days after Xuezhikang treatment, one patient claimed
discomfort in upper stomach and the symptom alleviated 10 days later.
DISCUSSION
Xuezhikang
capsule, developed and manufactured by Beijing WBL Peking University
Biotech Co., Ltd., is a pure natural medicine made up of and refined
from (Monascus purpureus) red yeast rice. One of its major active
ingredients is Lovastatin being a kind of HMG-CoA reductase inhibitor
that can directly reduce the synthesis of cholesterol. By increasing
LDL-C receptor, it can also promote cholesterol metabolism, reduce
serum TC and LDL-C concentration, inhibit the synthesis of fatty
acids and TG, dramatically raise HDL-C level and improve or regulate
disorders of lipid metabolic process. In addition, Xuezhikang also
contains many kinds of necessary amino acids and unsaturated fatty
acids that can protect liver from getting disease and enhance fat
transfer. [2] Studies show that Xuezhikang could decrease liver
coefficient (liver weight/body weight) of exogenous hyperlipoidemia
rabbit and alleviate histomorphological changes of liver. Thus,
it is considered that Xuezhikang can inhibit lipid deposition in
liver. [3] At present, there is very little literature on clinical
observation of the effects of Xuezhikang on fatty liver, in this
study, we treat 41 patients with Xuezhikang for 6 months. The findings
indicate that Xuezhikang possesses very significant performance
in lowering the concentrations of TC, TG and LDL-C and raising HDL-C
level. It also achieves clear effects on serum ALT and AST reduction.
Meanwhile, it significantly alleviates clinical symptoms and B-Mode
ultrosonogram of such patients. 6-month clinical applications without
any obvious side-effect strongly supports previous viewpoint and
indicates that Xuezhikang is an ideal and effective medicine to
treat fatty liver.
REFERENCES
1.
|
Zhang
Qisheng, et al. New Advances of Diagnosis for Fatty Liver, Practical
Internal Medicine, 1993, 13 (1):39. |
2.
|
Zheng
Xiuying. Curative Effect of Xuezhiokang on 40 Hyperlipoidemia,
Chinese Medicine Newsletter, 1999, 14 (7):22. |
3.
|
Kou
Wenrong. Outline of Fundamental and Clinical Study on Xuezhikang,
Chinese Journal of Internal Medicine, 1998, 37(6):365. |
|